BMI, leukemic load, and levels of PYY and ghrelin were measured at diagnosis, following the induction-consolidation phase, and at standard intervals prior to each treatment cycle in 9 patients with ALL. These measurements were compared to those of 9 healthy, age- and sex-matched control children. The gene discussed is GHRL; the disease is acute lymphoblastic leukemia.